Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors

por Pruett, Jacob E., Romero, Damian G., Yanes Cardozo, Licy L.
Publicado 2023

Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women

por Pruett, Jacob E, Lirette, Seth T, Romero, Damian G, Yanes Cardozo, Licy L
Publicado 2022

Androgen Receptor Blocker Improves the Cardiometabolic Profile in a Rat Model of Polycystic Ovary Syndrome, but at What Cost?

por Pruett, Jacob E, Everman, Steven, Fernandez, Edgar David Torres, Davenport, Kacey, Romero, Damian G, Cardozo, Licy L Yanes
Publicado 2021

Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome

por Pruett, Jacob E., Torres Fernandez, Edgar D., Everman, Steven J., Vinson, Ruth M., Davenport, Kacey, Logan, Madelyn K., Ye, Stephanie A., Romero, Damian G., Yanes Cardozo, Licy L.
Publicado 2021

Mitochondrial function and oxidative stress in white adipose tissue in a rat model of PCOS: effect of SGLT2 inhibition

por Pruett, Jacob E., Everman, Steven J., Hoang, Ngoc H., Salau, Faridah, Taylor, Lucy C., Edwards, Kristin S., Hosler, Jonathan P., Huffman, Alexandra M., Romero, Damian G., Yanes Cardozo, Licy L.
Publicado 2022